Wells Fargo’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-1,150
Closed -$18.9K 7818
2023
Q4
$18.9K Sell
1,150
-100
-8% -$1.57K ﹤0.01% 5654
2023
Q3
$9.66K Sell
1,250
-10,000
-89% -$54.2K ﹤0.01% 5817
2023
Q2
$58.6K Buy
11,250
+10,000
+800% +$51K ﹤0.01% 5353
2023
Q1
$6.71K Hold
1,250
﹤0.01% 5978
2022
Q4
$4.64K Hold
1,250
﹤0.01% 5795
2022
Q3
$7K Hold
1,250
﹤0.01% 5833
2022
Q2
$8K Hold
1,250
﹤0.01% 5861
2022
Q1
$9K Buy
1,250
+1,150
+1,150% +$11.3K ﹤0.01% 6328
2021
Q4
$1K Sell
100
-26
-21% -$430 ﹤0.01% 7111
2021
Q3
$3K Sell
126
-41
-25% -$1.22K ﹤0.01% 6522
2021
Q2
$7K Hold
167
﹤0.01% 6253
2021
Q1
$12K Sell
167
-9
-5% -$639 ﹤0.01% 6293
2020
Q4
$7K Hold
176
﹤0.01% 6100
2020
Q3
$7K Buy
176
+106
+151% +$5.48K ﹤0.01% 5968
2020
Q2
$4K Hold
70
﹤0.01% 6034
2020
Q1
$5K Buy
70
+31
+79% +$3.57K ﹤0.01% 5871
2019
Q4
$5K Buy
+39
New +$4.74K ﹤0.01% 6051

Wells Fargo's ORTX Position: Q1 2024 in Review

Wells Fargo sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2024, closing a stake of 1,150 shares — an estimated $18.9K sold.

Wells Fargo first reported a position in ORTX in Q4 2019 and held it in 17 quarters. The position peaked at $58.6K in Q2 2023. 0 funds tracked by Wall St. Rank hold ORTX as of Q1 2024.

  • Wells Fargo reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Wells Fargo sold 1,150 Orchard Therapeutics plc American Depositary Shares shares in Q1 2024, an estimated $18.9K.
  • Wells Fargo first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2019 and held it in 17 quarters.
  • Wells Fargo's Orchard Therapeutics plc American Depositary Shares position peaked at $58.6K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2024.

Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.